Sector News

Alexion appoints Francois Nader to Board

November 9, 2017
Life sciences

Alexion Pharmaceuticals, Inc. today announced that Francois Nader, M.D., has been appointed to the Company’s Board of Directors.

Dr. Nader is an accomplished leader in the biopharmaceutical industry with a proven track record of building and transforming companies, launching rare disease therapies, and creating significant shareholder value.

As President, Chief Executive Officer, and Executive Director of NPS Pharma from 2008 to 2015, Dr. Nader transformed the organization into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Dr. Nader currently serves as non-executive chairman of Acceleron Pharma, Inc. and on the boards of Advanced Accelerator Applications, Clementia Pharmaceuticals Inc., and private company ArRETT Neuroscience. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. He previously served on the North America Leadership Team of Aventis Pharma and its predecessor companies, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. He also led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.

David Brennan, Chairman of the Board, commented, “We are very pleased to welcome Francois to Alexion’s Board of Directors. Francois is a leading value-builder in the biotechnology industry with expertise in developing and delivering innovative therapies that address significant patient needs. His strong background in rare diseases across both commercial and R&D functions will be a valuable addition to our board.”

Dr. Nader added: “Alexion is a recognized global leader in rare diseases with an exciting future as it executes on a strategy to drive sustainable, long-term performance. As a member of the Board of Directors, I look forward to applying my life sciences experience to help guide the company’s future growth and success.”

Alexion also announced today that Director M. Michele Burns has advised the Board that she does not plan to stand for re-election at the Company’s next annual meeting of shareholders. As previously announced in September 2017, Director Alvin S. Parven advised the Board that he does not plan to stand for re-election at the Company’s next annual meeting of shareholders and will retire from the Board at the 2018 annual meeting. Alexion’s Board of Directors has retained Spencer Stuart to conduct a search for an additional Director. The Board is seeking candidates who represent a range of backgrounds, perspectives, skills, and expertise, with an emphasis on maintaining a diverse Board.

Source: Alexion

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend